Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Sunitinib as First-Line Therapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer [clinicaltrials:NCT00748163]
Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Sunitinib as First-Line Therapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer [clinicaltrials:NCT00748163]
Bio2RDF identifier
NCT00748163
Bio2RDF namespace
clinicaltrials
Bio2RDF uri
http://bio2rdf.org/clinicaltrials:NCT00748163
identifiers.org URI
actual enrollment [clinicaltrials_vocabulary:actual-enrollment]
arm group [clinicaltrials_vocabulary:arm-group]
authority [clinicaltrials_vocabulary:authority]
brief summary [clinicaltrials_vocabulary:brief-summary]
RATIONALE: Drugs used i ...... V non-small cell lung cancer.
brief title [clinicaltrials_vocabulary:brief-title]
Paclitaxel Albumin-Stabilized ...... IV Non-Small Cell Lung Cancer
clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]
clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]
condition [clinicaltrials_vocabulary:condition]
condition browse [clinicaltrials_vocabulary:condition-browse]
condition mesh [clinicaltrials_vocabulary:condition-mesh]
country [clinicaltrials_vocabulary:country]
detailed description [clinicaltrials_vocabulary:detailed-description]
OBJECTIVES:
Prim ...... ry 3 months for up to 1 year.
download date [clinicaltrials_vocabulary:download-date]
ClinicalTrials.gov processed this data on August 10, 2015
eligibility [clinicaltrials_vocabulary:eligibility]
firstreceived date [clinicaltrials_vocabulary:firstreceived-date]
2008-09-05T00:00:00Z
intervention [clinicaltrials_vocabulary:intervention]
intervention browse [clinicaltrials_vocabulary:intervention-browse]
is fda regulated [clinicaltrials_vocabulary:is-fda-regulated]
is section 801 [clinicaltrials_vocabulary:is-section-801]
keyword [clinicaltrials_vocabulary:keyword]
stage IV non-small cell lung cancer
lastchanged date [clinicaltrials_vocabulary:lastchanged-date]
2011-08-31T00:00:00Z
lead sponsor [clinicaltrials_vocabulary:lead-sponsor]
nct id [clinicaltrials_vocabulary:nct-id]
NCT00748163
number of arms [clinicaltrials_vocabulary:number-of-arms]
official title [clinicaltrials_vocabulary:official-title]
Phase II Study of ABI-007 Plus ...... for Non-Small Cell Lung Cancer
org study id [clinicaltrials_vocabulary:org-study-id]
overall official [clinicaltrials_vocabulary:overall-official]
overall status [clinicaltrials_vocabulary:overall-status]
oversight [clinicaltrials_vocabulary:oversight]
phase [clinicaltrials_vocabulary:phase]
responsible party [clinicaltrials_vocabulary:responsible-party]
secondary id [clinicaltrials_vocabulary:secondary-id]
0802M26201
source [clinicaltrials_vocabulary:source]
start date [clinicaltrials_vocabulary:start-date]
2008-08-01T00:00:00Z
study design [clinicaltrials_vocabulary:study-design]
study type [clinicaltrials_vocabulary:study-type]
url [clinicaltrials_vocabulary:url]
verification date [clinicaltrials_vocabulary:verification-date]
2011-08-01T00:00:00Z
why stopped [clinicaltrials_vocabulary:why-stopped]
Study has been abandoned for lack of available funding.
identifier
clinicaltrials:NCT00748163
title
Paclitaxel Albumin-Stabilized ...... IV Non-Small Cell Lung Cancer
@en
type
label
Paclitaxel Albumin-Stabilized ...... r [clinicaltrials:NCT00748163]
@en